Loss of p16 expression is a sensitive marker of CDKN2A homozygous deletion in malignant meningiomas. Tang V, Lu R, Mirchia K, Van Ziffle J, et al. Acta Neuropathol 2023 Feb 1. doi: 10.1007/s00401-023-02544.

Read + Share

Amedeo Smart

Independent Medical Education

Tang V, Lu R, Mirchia K, Van Ziffle J, et al. Loss of p16 expression is a sensitive marker of CDKN2A homozygous deletion in malignant meningiomas. Acta Neuropathol 2023 Feb 1. doi: 10.1007/s00401-023-02544.
PMID: 36723772